PMM-302
PMM-302 (PMMB-302) is a shikonin N-benzyl sophoridate derivative and a telomerase inhibitor. PMM-302 downregulates the telomerase core proteins DKC1 and NHP2 as well as TERT mRNA, and inhibits telomerase activity. PMM-302 induces G2/M phase cell cycle arrest and apoptosis, accompanied by downregulation of Bcl2, Bcl-XL, and FADD and upregulation of cleaved caspase-3 and cleaved caspase-9. PMM-302 can be used for lung cancer-related research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2763421-81-2
- Formel: C38H45BrN2O6
- Molecular Weight:705.68
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle Caspase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
Telomerase |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
8.05 μM
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by CCK8 assay.
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by CCK8 assay.
|
34922028 |
| MDA-MB-231 | IC50 |
4.72 μM
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability by CCK8 assay.
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability by CCK8 assay.
|
34922028 |
| MCF7 | IC50 |
7.12 μM
|
Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability by CCK8 assay.
Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability by CCK8 assay.
|
34922028 |
| A549 | IC50 |
2.71 μM
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability by CCK8 assay.
Antiproliferative activity against human A549 cells assessed as reduction in cell viability by CCK8 assay.
|
34922028 |
| L02 | IC50 |
93.81 μM
|
Cytotoxicity against non-cancerous human L0-2 cells assessed as reduction in cell viability by CCK8 assay.
Cytotoxicity against non-cancerous human L0-2 cells assessed as reduction in cell viability by CCK8 assay.
|
34922028 |
| Calu-3 | IC50 |
16.02 μM
|
Antiproliferative activity against human Calu-3 cells assessed as reduction in cell viability by CCK8 assay.
Antiproliferative activity against human Calu-3 cells assessed as reduction in cell viability by CCK8 assay.
|
34922028 |
| NCI-H460 | IC50 |
5.34 μM
|
Antiproliferative activity against human H460 cells assessed as reduction in cell viability by CCK8 assay.
Antiproliferative activity against human H460 cells assessed as reduction in cell viability by CCK8 assay.
|
34922028 |
| NCI-H1650 | IC50 |
5.45 μM
|
Antiproliferative activity against human H1650 cells assessed as reduction in cell viability by CCK8 assay.
Antiproliferative activity against human H1650 cells assessed as reduction in cell viability by CCK8 assay.
|
34922028 |
In Vitro
PMM-302 (PMMB-302) inhibits the proliferation of HeLa, MDA-MB-231, MCF-7, A549, Calu-3, H460, and H1650 cancer cells with IC50 values of 8.05, 4.72, 7.12, 2.71, 16.02, 5.34, and 5.45 μM, respectively; its IC50 against non-cancerous L0-2 cells is 93.81 μM[1].
PMM-302 (0-8 μM; 24 h) dose-dependently induces G2/M phase cell cycle arrest in A549 cells, with the proportion of cells in G2/M phase increasing from approximately 11.30% in the control group to approximately 23.16%, 34.42%, and 44.53% at 2, 4, and 8 μM, respectively[1].
PMM-302 (4 μM; 0-36 h) time-dependently increases the proportion of cells in G2/M phase in A549 cells, reaching 53.40% at 36 h[1].
PMM-302 (0-4 μM; 24 h) dose-dependently induces apoptosis in A549 cells, with the proportion of late apoptotic cells increasing to 39.0% at 4 μM[1].
PMM-302 (4 μM; 0-36 h) time-dependently increases the proportion of apoptotic cells in A549 cells[1].
PMM-302 (0-8 μM) downregulates Bcl2, Bcl-XL, and FADD and upregulates cleaved caspase-3 and cleaved caspase-9 in a concentration-dependent manner in A549 cells, supporting its apoptosis-inducing effect[1].
PMM-302 (0-8 μM) downregulates the telomerase core proteins DKC1 and NHP2 as well as TERT mRNA in A549 cells, and inhibits telomerase-related activity in a dose-dependent manner, with the most pronounced downregulation of DKC1 and NHP2 at 8 μM; its telomerase inhibitory effect is weaker than that of BIBR1532 at the same concentration[1].
Molecular docking predicts that PMM-302 localizes to the telomerase active site and forms 1 hydrogen bond with THR232[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549
-
Concentration:0, 2, 4, 8 μM (for 24 h); 4 μM (for time-dependent assay)
-
Incubation Time:24 h (for dose-dependent assay); 0, 12, 24, 36 h (for time-dependent assay)
-
Result:Induced G2/M phase arrest in a dose-dependent manner with percentages of cells in G2/M phase of 11.30% (control), 23.16% (2 μM), 34.42% (4 μM), and 44.53% (8 μM).
Induced G2/M phase arrest in a time-dependent manner with maximum accumulation of 53.40% cells after treatment with 4 μM for 36 h.
-
Cell Line:A549
-
Concentration:0, 2, 4 μM (for 24 h); 4 μM (for time-dependent assay)
-
Incubation Time:24 h (for dose-dependent assay); 0, 12, 24, 36 h (for time-dependent assay)
-
Result:Induced apoptosis in a dose-dependent manner with percentages of cells in late apoptosis of 5.85% (control), 29.2% (2 μM), and 39.0% (4 μM).
Induced apoptosis in a time-dependent manner with maximum accumulation of 36.6% cells in late apoptosis within 24 h.
Chemical Information
-
CAS. Nr. 2763421-81-2
-
Molecular Weight 705.68
-
Formel C38H45BrN2O6
-
SMILES
C/C(C)=C\C[C@H](C(C(C1=C(O)C=CC(O)=C12)=O)=CC2=O)OC(CCC[C@@H]3[C@]4([H])[C@]5([H])[C@](CCCN5CCC4)([H])CN3CC6=C(C=CC=C6)Br)=O
-
Synonyms
PMMB-302
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)